Show simple item record

dc.contributor.authorWieduwilt, Matthew J
dc.contributor.authorMetheny, Leland
dc.contributor.authorZhang, Mei-Jie
dc.contributor.authorWang, Hai-Lin
dc.contributor.authorEstrada-Merly, Noel
dc.contributor.authorMarks, David I
dc.contributor.authorAl-Homsi, A Samer
dc.contributor.authorMuffly, Lori
dc.contributor.authorChao, Nelson
dc.contributor.authorRizzieri, David
dc.contributor.authorGale, Robert Peter
dc.contributor.authorGadalla, Shahinaz M
dc.contributor.authorCairo, Mitchell
dc.contributor.authorMussetti, Alberto
dc.contributor.authorGore, Steven
dc.contributor.authorBhatt, Vijaya Raj
dc.contributor.authorPatel, Sagar S
dc.contributor.authorMichelis, Fotios V
dc.contributor.authorInamoto, Yoshihiro
dc.contributor.authorBadawy, Sherif M
dc.contributor.authorCopelan, Edward
dc.contributor.authorPalmisiano, Neil
dc.contributor.authorKharfan-Dabaja, Mohamed A
dc.contributor.authorLazarus, Hillard M
dc.contributor.authorGanguly, Siddhartha
dc.contributor.authorBredeson, Christopher
dc.contributor.authorDiaz Perez, Miguel Angel
dc.contributor.authorCassaday, Ryan
dc.contributor.authorSavani, Bipin N
dc.contributor.authorBallen, Karen
dc.contributor.authorMartino, Rodrigo
dc.contributor.authorWirk, Baldeep
dc.contributor.authorBacher, Ulrike
dc.contributor.authorAljurf, Mahmoud
dc.contributor.authorBashey, Asad
dc.contributor.authorMurthy, Hemant S
dc.contributor.authorYared, Jean A
dc.contributor.authorAldoss, Ibrahim
dc.contributor.authorFarhadfar, Nosha
dc.contributor.authorLiu, Hongtao
dc.contributor.authorAbdel-Azim, Hisham
dc.contributor.authorWaller, Edmund K
dc.contributor.authorSolh, Melhem
dc.contributor.authorSeftel, Matthew D
dc.contributor.authorvan der Poel, Marjolein
dc.contributor.authorGrunwald, Michael R
dc.contributor.authorLiesveld, Jane L
dc.contributor.authorKamble, Rammurti T
dc.contributor.authorMcGuirk, Joseph
dc.contributor.authorMunker, Reinhold
dc.contributor.authorCahn, Jean-Yves
dc.contributor.authorLee, Jong Wook
dc.contributor.authorFreytes, César O
dc.contributor.authorKrem, Maxwell M
dc.contributor.authorWinestone, Lena E
dc.contributor.authorGergis, Usama
dc.contributor.authorNathan, Sunita
dc.contributor.authorOlsson, Richard F
dc.contributor.authorVerdonck, Leo F
dc.contributor.authorSharma, Akshay
dc.contributor.authorRingdén, Olle
dc.contributor.authorFriend, Brian D
dc.contributor.authorCerny, Jan
dc.contributor.authorChoe, Hannah
dc.contributor.authorChhabra, Saurabh
dc.contributor.authorNishihori, Taiga
dc.contributor.authorSeo, Sachiko
dc.contributor.authorGeorge, Biju
dc.contributor.authorBaxter-Lowe, Lee Ann
dc.contributor.authorHildebrandt, Gerhard C
dc.contributor.authorde Lima, Marcos
dc.contributor.authorLitzow, Mark
dc.contributor.authorKebriaei, Partow
dc.contributor.authorHourigan, Christopher S
dc.contributor.authorAbid, Muhammad Bilal
dc.contributor.authorWeisdorf, Daniel J
dc.contributor.authorSaber, Wael
dc.date.accessioned2022-01-25T12:59:34Z
dc.date.available2022-01-25T12:59:34Z
dc.date.issued2022-01
dc.identifier.urihttp://hdl.handle.net/10713/17776
dc.description.abstractThe role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.en_US
dc.description.urihttps://doi.org/10.1182/bloodadvances.2021004916en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8753217/en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofBlood Advancesen_US
dc.rights© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.en_US
dc.titleHaploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.en_US
dc.typeArticleen_US
dc.identifier.doi10.1182/bloodadvances.2021004916
dc.identifier.pmid34547770
dc.source.journaltitleBlood advances
dc.source.volume6
dc.source.issue1
dc.source.beginpage339
dc.source.endpage357
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record